Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial

• Main Authors: Barbara de Barros, -, Saba M Lambert, -, Mahesh Shah, -, Vivek V Pai, -, Joydeepa Darlong, -, Benjamin Jewel Rozario, -, Medhi Denisa Alinda, -, Anna M Sales, -, Shimelis Doni, -, Deanna A Hagge, -, Dilip Shrestha, -, M. Yulianto Listiawan, -, Abeba M Yitaye, -, Jose A C Nery, -, Kapil D Neupane, -, Vivianne L A Dias, -, C. Ruth Butlin, -, Peter G Nicholls, -, Diana Lockwood, -, Stephen L Walker, -
• Format: Article PeerReviewed
• Language: English; English; English
• Published: BMJ Publishing Group 2021
• Subjects: R Medicine (General); RL Dermatology
• Online Access: https://repository.unair.ac.id/119568/1/Artikel.pdf; https://repository.unair.ac.id/119568/2/Karil.pdf; https://repository.unair.ac.id/119568/3/Similarity.pdf; https://repository.unair.ac.id/119568/; https://bmjopen.bmj.com/content/10/11/e037700.long; http://dx.doi.org/10.1136/bmjopen-2020-037700

Introduction Erythema nodosum leprosum (ENL) is an immunological complication of leprosy. ENL results in morbidity and disability and if it is not treated can lead to death. The current treatment consists of thalidomide or high doses of oral corticosteroids for prolonged periods. Thalidomide is not...